How the Heart Failure Market Is Growing in 2025 | What New Treatments Are Coming for Heart Failure

The heart failure market size was valued at US$ 6.6 billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 markets to reach US$ 18.5 billion by 2035, exhibiting a growth rate (CAGR) of 9.81% during 2025-2035.

As cardiovascular diseases are still on the rise, so are changes in the heart failure market for 2025. Heart failure is a chronic disease where the heart fails to pump blood effectively, causing fatigue, shortness of breath, and other medical issues. With the rising number of old people, risks of having such factors as high blood pressure and diabetes also grow, and as survival rates rise for heart attacks globally, people living with heart failure are also on the rise.

With increasing rates of heart failure in 2025, market growth is driven on a grand scale. As per recent estimates, the current number of individuals living with heart failure worldwide is 60 million plus, and it's expected to have a steady increase. Changes in lifestyle like diet, activity, obesity, stress, etc. are causing this phenomenon to a great extent in developed nations and emerging economies.

Request For a Sample Report: https://www.imarcgroup.com/heart-failure-market/requestsample

On the other hand, more advances are being made in drug development. New classes of drugs hold more effective symptom control and survival. One of the leading advancements is the expanded use of the SGLT2 inhibitors originally discovered for diabetes. They are now established to reduce the rate of death and hospitalization by a substantial measure in patients with heart failure. Thus, such medicines are emerging as a new standard of treatment for heart failure patients, given the double advantage of SGLT2 inhibitors on heart as well as kidney function.

Another significant trend in 2025 is the increasing application of digital health technologies in the management of heart failure. Remote patient monitoring devices, intelligent wearables, and mobile health apps are assisting doctors in monitoring patient health information in real time. These devices facilitate early detection of deteriorating symptoms, which aids in timely intervention and minimizes emergency hospitalization. Artificial intelligence is also being incorporated into diagnostic devices to forecast disease progression and tailor treatment regimens.

With regard to device development, implantable cardiac devices and minimally invasive techniques are broadening the treatment horizon. Left ventricular assist devices (LVADs), implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices are increasingly being employed in patients with end-stage heart failure. These technologies are enhancing quality of life and survival in patients with non responder medications.

The market is also underpinned by robust investment in clinical trials and collaborations between pharmaceutical firms, healthcare systems, and technology companies. These partnerships are speeding up the development of new treatments and expanding access to care, especially in underserved areas.

In total, the heart failure market in 2025 is fueled by innovation, increasing disease burden, and movement toward comprehensive care solutions. As technology advances and knowledge improves, the future for heart failure patients keeps getting brighter. By diagnosing early, offering personalized care, and providing digital assistance, heart failure is being managed more efficiently and patient-oriented than ever.

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

According to the report, the United States has the largest patient pool for heart failure and also represents the largest market for its treatment.

Buy Full Report @ https://www.imarcgroup.com/checkout?id=6893&method=809

Key Highlights:

Heart failure affects more than 65 million people worldwide and is most commonly caused by heart conditions like ischemic heart disease, cardiomyopathy, or high blood pressure.

Heart failure affects around 6.7 million Americans over the age of 20, and the number is anticipated to increase to 8.5 million by 2030.

The lifetime risk of heart failure has risen to 24%; approximately 1 in every 4 individuals will develop heart failure in their lifetime.

The prevalence of heart failure, as examined by systematic echocardiographic screening, is significantly higher, even reaching 11.8% in a meta-analysis.

Heart failure directly causes around 8.5% of all heart disease deaths in the United States.

IMARC Group Offers Other Reports:

Acute Pain Market -https://www.openpr.com/news/4000344/acute-pain-market-in-7-major-markets-to-reach-usd-129-8-million

Obesity Market - https://www.openpr.com/news/4000565/obesity-market-across-7-key-regions-projected-to-hit-usd-76-6

Autism Spectrum Disorder Market - https://www.openpr.com/news/4000842/autism-spectrum-disorder-market-across-7-key-regions-projected

Erectile Dysfunction Market - https://www.openpr.com/news/4001202/erectile-dysfunction-market-across-7-key-regions-projected

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market https://www.openpr.com/news/4001892/acute-bacterial-skin-and-skin-structure-infections-absssi

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.